Adma Biologics reported $37.82M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Adma Biologics USD 37.82M 7.51M Jun/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Novavax USD 17.53M 219.91M Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Takeda JPY 192.43B 79.23B Sep/2026